Vivaldi Capital Management’s Theriva Biologics TOVX Stock Holding History

Vivaldi Capital Management’s Portfolio TOVX Stock Details TOVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-12	Closed	-$24K	–	151
2018 Q2	$24K	Hold	12	–	–	0.02%	130
2018 Q1	$32K	Hold	12	–	–	0.02%	130
2017 Q4	$51K	Buy	12 +1	+9%	+$6.25K	0.04%	124
2017 Q3	$89K	Hold	11	–	–	0.38%	67
2017 Q2	$54	Buy	11 +5	+83%	+$24.9K	﹤0.01%	86
2017 Q1	$33	Buy	+6	New	+$41.9K	﹤0.01%	131

Other funds holding TOVX

Third Security Radford, Virginia $241M AUM 45.43% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

TSS

Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

LTFS

Ladenburg Thalmann Financial Services Miami, Florida $15.9B AUM 25.16% 1-Year Est. Return

Vivaldi Capital Management's TOVX Position: Q3 2018 in Review

Vivaldi Capital Management sold out of Theriva Biologics (TOVX) in Q3 2018, closing a stake of 12 shares — an estimated $24K sold.

Vivaldi Capital Management first reported a position in TOVX in Q1 2017 and held it in 6 quarters. The position peaked at $89K in Q3 2017. 22 funds tracked by Wall St. Rank hold TOVX as of Q3 2018.

Vivaldi Capital Management reported no remaining Theriva Biologics position as of Q3 2018 after selling out during the quarter.
Vivaldi Capital Management sold 12 Theriva Biologics shares in Q3 2018, an estimated $24K.
Vivaldi Capital Management first reported a position in Theriva Biologics in Q1 2017 and held it in 6 quarters.
Vivaldi Capital Management's Theriva Biologics position peaked at $89K in Q3 2017.
22 funds tracked by Wall St. Rank held Theriva Biologics as of Q3 2018.

Based on Vivaldi Capital Management's 13F filing for Q3 2018, filed 14 Nov 2018.